Targets › PTGER1
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 4; Other; next expected readout Dec 2026.
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. (UniProt, P34995)
Open in Phaseline: the race on PTGER1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| HaEmek Medical Center, Israel | Dinoprostone Prostaglandin E2 receptor agonist | PTGER1, PTGER4, PTGER2, PTGER3 | Phase 4 | Induction of Labor | Jan 2027 |
| Ghufran Dhari Awad | Prostaglandin E1 Prostaglandin E1 receptor agonist | PTGER1, PTGER2, PTGER3, PTGER4 | Phase 2 | Accelerated Orthodontic Tooth Movement | Dec 2026 |
Accelerated Orthodontic Tooth Movement (1) Induction of Labor (1)
small molecule (2)
Ghufran Dhari Awad (1) HaEmek Medical Center, Israel (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.